Summary & Overview
HCPCS Level II J9000: Doxorubicin Hydrochloride Injection, 10 mg
Headline: HCPCS Level II code J9000 denotes doxorubicin hydrochloride injections used in systemic chemotherapy. Lead: HCPCS Level II code J9000 identifies a 10 mg unit of doxorubicin hydrochloride (Adriamycin), an established cytotoxic agent used across multiple malignancies in infusion-based oncology care. Why it matters: Accurate use of J9000 is critical for clinical documentation, drug inventory control, and payer adjudication for chemotherapy services provided in outpatient infusion settings nationwide. Key payers covered: Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare. What readers will learn: This briefing explains the clinical and billing context for J9000, outlines common billing considerations tied to chemotherapy drug administration, and distinguishes this formulation from related lipid formulations billed under separate codes. It summarizes payer coverage landscape and common claim-line elements relevant to infusion services. Clinical context: Doxorubicin is a foundational anthracycline chemotherapy used for a range of solid tumors and hematologic malignancies; J9000 captures the drug product delivered per 10 mg unit. Administrative context: The code applies to drug reporting on the claim line for infusion visits typically performed in outpatient infusion centers. Data limitations: Service-line metadata is missing from the input; specifics about local coverage determinations or state-level policy are not provided. Readers should expect concise benchmarks for claim reporting practices, common clinical indications linked to use of the drug, and a summary of payer presence without state-specific coverage directives.
Billing Code Overview
HCPCS Level II code J9000 represents an injection of doxorubicin hydrochloride (Adriamycin), 10 mg. This code is used to report the chemotherapy drug itself when administered as part of an oncology treatment regimen.
Service Type: Chemotherapy drug administration
Typical Site of Service: Infusion setting (for example, outpatient infusion center)
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with a confirmed diagnosis of metastatic breast cancer presents to an outpatient infusion center for systemic chemotherapy. The treatment plan orders doxorubicin hydrochloride for administration via intravenous infusion as part of a multi-agent regimen. The clinical workflow includes verification of the oncologist’s chemotherapy order, review of recent labs (complete blood count, hepatic and renal function), venous access assessment (peripheral IV or central line), premedication as indicated, preparation of the drug by pharmacy in an appropriate sterile environment, administration in the infusion chair by an oncology nurse, observation for infusion-related reactions, documentation of administered dose and lot number, and billing for the drug using HCPCS Level II code J9000 per 10 mg unit.
Coding Specifications
-
Modifiers:
-
JW- Drug amount discarded/not administered to any patient. Use when a portion of the dispensed vial is discarded and the discarded amount must be reported separately from the administered amount. -
59- Distinct Procedural Service. Use when a service or procedure that is not normally reported together is distinct because it was performed at a separate session or was a separate encounter. -
Provider Taxonomies:
-
207RH0003X- Hematology & Oncology Physician -
207RX0202X- Medical Oncology Physician -
2084P0800X- Psychiatry & Neurology Physician
Related Diagnoses
C50.911- Malignant neoplasm of unspecified site of right female breast
Clinical relevance: Doxorubicin is commonly used in curative or palliative regimens for breast cancer; this diagnosis commonly indicates systemic chemotherapy where J9000 may be billed.
C34.90- Malignant neoplasm of unspecified part of unspecified bronchus or lung
Clinical relevance: Lung cancer may be treated with systemic cytotoxic agents; doxorubicin may be part of selected regimens or clinical protocols where J9000 is applicable.
C18.9- Malignant neoplasm of colon, unspecified
Clinical relevance: Colorectal malignancies sometimes require systemic chemotherapy; doxorubicin use is less common but may be relevant in certain protocols billed with J9000.
C61- Malignant neoplasm of prostate
Clinical relevance: Prostate cancer treatment is primarily hormonal and radiotherapeutic, but certain advanced or experimental regimens may involve cytotoxic agents billed with J9000 if applicable.
C25.9- Malignant neoplasm of pancreas, unspecified
Clinical relevance: Pancreatic cancer often requires systemic chemotherapy; doxorubicin may be used in some regimens or trials and would be billed with J9000 when administered.
Related Codes
-
J9001- Injection, doxorubicin hydrochloride, all lipid formulations, 10 mg -
Relationship to primary code:
-
J9001is a formulation-specific HCPCS Level II code that describes doxorubicin supplied in lipid formulations and serves as an alternative billing code when that specific formulation is used instead of the conventional formulation reported withJ9000. -
Common use in workflow:
-
J9001is used instead ofJ9000when the lipid-formulated product is dispensed. These codes are alternatives and are not reported together for the same administered milligram amount.
National Reimbursement Benchmarks
National mean commercial rates for HCPCS Level II code J9000 are materially higher than the Medicare value; BUCA (average commercial) mean rate of $4.49 exceeds Medicare (no numeric Medicare mean provided in the input) and is lower than Aetna's mean of $6.40. Aetna posts the highest national mean rate among the listed payers.
Rate dispersion (P75 minus P25) is smallest for Cigna Health and BUCA, both showing tight distributions (P75–P25 = 0 for Cigna and 0.5 for BUCA). Blue Cross Blue Shield shows wider dispersion (P75–P25 = 1.5) and UnitedHealthcare also shows notable spread (P75–P25 = 1). Aetna's interquartile spread is 1.0. The table and chart below present the full breakdown.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.